Tingyi H1 2026: Net Profit Rises 7.5% to RMB 2.89 Billion as Gross Margin Widens to 35.8%

Bulletin Express
Aug 11

Tingyi (Cayman Islands) Holding Corp. reported solid interim results for the six months ended 30 June 2026, with profit for the period climbing 7.5% year-on-year (YoY) to RMB 2.89 billion. Profit attributable to shareholders reached RMB 2.43 billion, up 7.1%, while adjusted attributable profit—excluding one-off asset disposals—advanced 15.2% to the same level.

Revenue edged up 1.1% YoY to RMB 40.54 billion, driven by balanced performance in the Group’s two core divisions: • Instant Noodles posted sales of RMB 13.73 billion (+2.0% YoY), contributing 33.9% of total revenue. • Beverages generated RMB 26.54 billion (+0.7% YoY), accounting for 65.5% of the top line.

Group gross margin expanded 1.3 percentage points to 35.8%, reflecting product-mix optimisation in both segments. Instant Noodles’ margin improved 2.5 percentage points to 30.3%, while Beverages gained 0.7 percentage points to 38.4%. EBITDA increased 3.6% YoY to RMB 5.64 billion.

Operating costs remained tightly controlled; distribution expenses held flat at 22.8% of revenue and administrative expenses accounted for 3.8%. Finance costs dipped 2.5% to RMB 157.28 million. Basic earnings per share rose to RMB 43.16 cents from RMB 40.30 cents.

Balance-sheet strength improved further. Cash and bank balances (including long-term time deposits) stood at RMB 23.67 billion, up RMB 4.18 billion versus end-2025, driven by a net operating cash inflow of RMB 3.34 billion. Net cash position widened to RMB 6.28 billion, and the gearing ratio improved to –48.6%. Total assets reached RMB 59.97 billion, while the debt ratio increased to 72.9% due to higher short-term borrowings and payables.

Working-capital metrics remained healthy: inventory days shortened to 14.6 from 16.3, and trade-receivable days ticked up slightly to 7.7. The current ratio improved to 0.8 from 0.7.

The Board did not declare an interim dividend.

Management believes ongoing product premiumisation, health-oriented innovation and omni-channel expansion will underpin the company’s high-quality growth strategy in the second half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10